Patents matching “antagonist”

US 6878709

3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists

Pharmacopeia Drug Discovery, Inc. · Granted Apr 12, 2005 · Expires Apr 7, 2025

US 6872728

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. · Granted Mar 29, 2005 · Expires Mar 24, 2025

US 6849429

Viral pseudo-capsids including assembly agonists and antagonists

The Board of Regents of the University of Texas System · Granted Feb 1, 2005 · Expires Jan 27, 2025

US 6846799

Preventing airway mucus production by administration of EGF-R antagonists

The Regents of the University of California · Granted Jan 25, 2005 · Expires Jan 20, 2025

US 6811780

Methods of using cytokine antagonists to treat HIV infection and AIDS

REGENERON PHARMACEUTICALS, INC. · Granted Nov 2, 2004 · Expires Oct 28, 2024

US 6756038

Agonist and antagonist peptides of carcinoembryonic antigen (CEA)

The United States of America, as represented by the Department of Health and Human Services · Granted Jun 29, 2004 · Expires Jun 24, 2024

US 6750350

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. · Granted Jun 15, 2004 · Expires Jun 10, 2024

EP 1425277

HARNSTOFF-DERIVATE ALS VANILLOID-REZEPTOR-ANTAGONISTEN FÜR DIE SCHMERZBEHANDLUNG

SMITHKLINE BEECHAM PLC [GB] · Granted Jun 9, 2004 · Expires Jun 4, 2024

US 6747034

CRF receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. · Granted Jun 8, 2004 · Expires Jun 3, 2024

US 6740656

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. · Granted May 25, 2004 · Expires May 20, 2024

US 6723721

CRF receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. · Granted Apr 20, 2004 · Expires Apr 15, 2024

US 6692741

Treatment of acute lung injury and fibrosis with antagonists of &bgr;6-specific antibodies

The Regents of the University of California · Granted Feb 17, 2004 · Expires Feb 12, 2024

US 6693202

Muscarinic receptor antagonists

Theravance, Inc. · Granted Feb 17, 2004 · Expires Feb 12, 2024

US 6677340

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. · Granted Jan 13, 2004 · Expires Jan 8, 2024

US 6673796

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. · Granted Jan 6, 2004 · Expires Jan 1, 2024

US 6630124

Combination therapy with VIP antagonist

The United States of America, as represented by the Department of Health and Human Services · Granted Oct 7, 2003 · Expires Oct 2, 2023

US 6620825

Adenosine A3 receptor antagonists

Takeda Chemical Industries Ltd. · Granted Sep 16, 2003 · Expires Sep 11, 2023

US 6620802

Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist

Corcept Therapeutics Incorporated · Granted Sep 16, 2003 · Expires Sep 11, 2023

US 6608197

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. · Granted Aug 19, 2003 · Expires Aug 14, 2023

US 6589547

Sustained-release preparation for AII antagonist, production and use thereof

Takeda Chemical Industries Ltd. · Granted Jul 8, 2003 · Expires Jul 3, 2023

US 6586413

Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists

The United States of America, as represented by the Department of Health and Human Services · Granted Jul 1, 2003 · Expires Jun 26, 2023

US 6583143

CRF receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. · Granted Jun 24, 2003 · Expires Jun 19, 2023

US 6569431

Recombinant antibody fragments as autoantibody antagonists

The Regents of the University of California · Granted May 27, 2003 · Expires May 22, 2023

US 6566324

Preventing airway mucus production by administration of EGF-R antagonists

The Regents of the University of California · Granted May 20, 2003 · Expires May 15, 2023